Thomas Pfisterer has served as a member of the board of directors of Imvax since 2019.
In addition to his position as member of the board of directors of Imvax, Inc., Thomas currently serves on the boards of directors of several other companies, including biotech companies ADC Therapeutics (NYSE:ADCT) (Epalinges, CH) and InSphero AG (Schlieren, CH), or pharma company Sermonix Pharmaceuticals Inc. (Columbus (OH), US).
Thomas Pfisterer also holds a senior management role at WILD Group Management AG heading the Direct Investments activities of the WILD Family Investment Office since the beginning of 2015.
He joined the Family Office following the sale of WILD Flavors GmbH, one of the world’s leading suppliers of natural ingredients to the food and beverage industry, for which he served as Head of Strategic Development directing the company’s global M&A activities since October 2011.
Previously, Mr. Pfisterer worked in the investment banking division of Morgan Stanley Bank AG in Frankfurt, focusing on M&A and capital market transactions for German healthcare clients.
Mr. Pfisterer holds a Master in Finance (MPhil) from Cambridge University, UK, as well as a Bachelor in Economics (B.A. HSG) and a Bachelor in Business Administration (B.A. HSG), both from University of St. Gallen, CH.